ReNeuron secures £1.8m grant to optimize cell therapy manufacturing processes

The grant, entitled "Cell2Sell – commercial scale next generation platform for allogeneic stem cell production", has been awarded under Innovate UK's Cell & Gene Therapies Industrial Manufacture grant scheme and will fund a collaborative programme of work to be undertaken by ReNeuron, as lead participant, and its collaborators on the grant, the Cell & Gene Therapy Catapult.

The grant will fund key process development activities relating to up-scaled commercial manufacture of ReNeuron's cell therapy candidates.  These include the development of robust manufacturing processes utilising next generation technology and techniques that will enable the production of ReNeuron's therapeutic candidates at a commercial scale.

Commenting on the funding selection, Sharon Grimster, General Manager, Wales, at ReNeuron, said:

"We are delighted to have won this prestigious and highly competitive grant from Innovate UK.  It enables us to further pursue and optimise our cell therapy manufacturing processes as our therapeutic programmes get closer to market. 

“The grant award will also assist ReNeuron in the execution of its strategy to ultimately bring the manufacture of its cell therapy candidates in-house to meet demand following market approval."